Clinical trials for treatments to prevent recurring strokes typically only include participants who have little to no disability from a prior stroke. A new Yale study finds that leaving patients with ...
OCEANIC-STROKE shows asundexian cuts ischemic stroke recurrence by 26% in patients taking standard antiplatelet therapy, with no major bleeding increase. Asundexian is a direct oral inhibitor of FXIa ...
According to Lin, whose research focuses on stroke recovery and rehabilitation, previous studies at UAB, like the REGARDS study, have looked at disparities regarding stroke care. This prompted him and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results